Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Adamson

Showing results (261-270 of 342) with videos related to

Pageof 35
Sort By:
Neuro-Oncology|August 4, 2021
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group reportJack M Su, Lindsay B Kilburn, David B Mansur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group studyTerzah M Horton, Debananda Pati, Sharon E Plon, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
European Journal of Clinical Pharmacology|October 3, 2009
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 monthsJohn T Mondick, Brendan M Johnson, Lynda J Haberer, et al.
Sexually Transmitted Infections|October 17, 2025
Field evaluation of a dual treponemal/non-treponemal point-of-care test for syphilis within an HIV pre-exposure prophylaxis programme in Hanoi, VietnamUrsula Biba, Hao T M Bui, Linh Tp Nguyen, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212)Emily Greengard, Yael P Mosse, Xiaowei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group studyErin Cooney-Qualter, Mark Krailo, Anne Angiolillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium reportBrigitte C Widemann, Aerang Kim, Elizabeth Fox, et al.
Experimental Hematology|December 10, 2023
Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsMona A Alqazzaz, Genna M Luciani, Victoria Vu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomeBrigitte C Widemann, Frank M Balis, AeRang Kim, et al.
Pageof 35

Showing results (261-270 of 342) with videos related to

Sort By:
Pageof 35
Neuro-Oncology|August 4, 2021
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group reportJack M Su, Lindsay B Kilburn, David B Mansur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group studyTerzah M Horton, Debananda Pati, Sharon E Plon, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
European Journal of Clinical Pharmacology|October 3, 2009
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 monthsJohn T Mondick, Brendan M Johnson, Lynda J Haberer, et al.
Sexually Transmitted Infections|October 17, 2025
Field evaluation of a dual treponemal/non-treponemal point-of-care test for syphilis within an HIV pre-exposure prophylaxis programme in Hanoi, VietnamUrsula Biba, Hao T M Bui, Linh Tp Nguyen, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212)Emily Greengard, Yael P Mosse, Xiaowei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group studyErin Cooney-Qualter, Mark Krailo, Anne Angiolillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium reportBrigitte C Widemann, Aerang Kim, Elizabeth Fox, et al.
Experimental Hematology|December 10, 2023
Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsMona A Alqazzaz, Genna M Luciani, Victoria Vu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomeBrigitte C Widemann, Frank M Balis, AeRang Kim, et al.
Pageof 35